کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6259119 | 1612983 | 2013 | 7 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Research reportEffects of a dopamine D1 agonist on ketamine-induced spatial working memory dysfunction in common marmosets Research reportEffects of a dopamine D1 agonist on ketamine-induced spatial working memory dysfunction in common marmosets](/preview/png/6259119.png)
- Cognitive function was evaluated in common marmosets using the CANTAB SWM test.
- Subanesthetic doses of ketamine induced cognitive deficiency in the marmosets.
- A selective dopamine receptor D1 agonist was effective at ameliorating this dysfunction.
- This model could be useful for predicting the clinical efficacy of treatments for cognitive disorders.
It is considered that functional deficiency of the NMDA receptors in the prefrontal cortex (PFC) is one of the causes of the cognitive impairment observed in schizophrenia. As non-human primates display more developed PFC than rodents, they are considered to be useful experimental animals for improving the predictive validity of models used to discover new drugs for treating cognitive dysfunction. The aim of this study was to develop a convenient model of the cognitive impairment observed in schizophrenia using common marmosets and the CANTAB system and to test whether a full agonist of the dopamine D1 receptor (SKF-81297) was effective against the cognitive impairment induced in this model. We administered the NMDA receptor antagonist ketamine (1.5-16Â mg/kg, i.m.) to the marmosets to induce cognitive impairment and then evaluated their working memory function using the CANTAB spatial working memory (SWM) test. The marmosets' working memory was impaired by subanesthetic doses of ketamine. Next, we tested the effect of SKF-81297 (3 or 10Â mg/kg, p.o.) on this ketamine-induced cognitive dysfunction. The marmosets were administered SKF-81297 30Â min before the ketamine injection. Pretreatment with SKF-81297 reversed the ketamine-induced cognitive deficiency. In this study, we found that a D1 receptor agonist, which has been reported to enhance cognitive function, reversed ketamine-induced cognitive impairment in marmosets, which suggests that our marmoset model could be a useful tool for predicting the clinical efficacy of cognitive-enhancing drugs.
Journal: Behavioural Brain Research - Volume 249, 15 July 2013, Pages 109-115